The use of cyclosporine in dermatology

Journal of Drugs in Dermatology

Volumn 11, Issue 8, 2012, Pages 979-987

  Dehesa, Luis ^a   Abuchar, Adriana ^a   Nuno Gonzalez, Almudena ^a   Vitiello, Magalys ^a   Kerdel, Francisco A ^a  

^a UNIVERSITY OF MIAMI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; RETINOID; RITUXIMAB; SUNSCREEN; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ANTIBODY;

ATOPIC DERMATITIS; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; BLISTER; CONNECTIVE TISSUE DISEASE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; GINGIVA HYPERPLASIA; HEADACHE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; LYMPHOPROLIFERATIVE DISEASE; MAGNESIUM BLOOD LEVEL; MALIGNANT NEOPLASTIC DISEASE; MYALGIA; MYCOSIS; OFF LABEL DRUG USE; OPPORTUNISTIC INFECTION; PARASITOSIS; PARESTHESIA; PSORIASIS; REVIEW; SIDE EFFECT; SKIN CANCER; SKIN INFLAMMATION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; UREA NITROGEN BLOOD LEVEL; VIRUS INFECTION;

CHRONIC DISEASE; CYCLOSPORINE; DERMATITIS, ATOPIC; DERMATOMYOSITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; PRURIGO; PSORIASIS; PYODERMA GANGRENOSUM; SKIN DISEASES; SWEET SYNDROME; URTICARIA;

EID: 84866145878     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. Amor K, Catriona R, et al. The use of cyclosporine in dermatology: Part I. J Am Acad Dermatol 2010; 63: 925-46.
2. Mueller W, Hermann B. Cyclosporin A for psoriasis. N Engl J Med 1979;301: 555.
3. Griffiths CEM, Powles AV, Leonard JN, Fry L. Clearance of psoriasis with low dose cyclosporine. Br Med J 1986; 293: 731-2.
4. Feutren G, Friend D, Timonen P, Laburte C. Cyclosporin monitoring in psoriasis. Lancet 1990;335: 866-7.
5. Timonen P, Friend D, Abeywickrama K, Laburte C, Von Graffenried B, Feutren G. Efficacy of low-dose cyclosporine A in psoriasis: results of dose-finding studies. Br J Dermatol 1990;122:33-9.
6. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324:277-84.
7. Christophers E, Mrowietz U, Henneick HH, Färber L, Welzel D. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriaisis. J Am Acad Dermatol 1992;26:86-90.
8. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85.
9. Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991;324: 277-284.
10. Ho VC, Griffiths CE, Berth-Jones J et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001; 44: 643-651.
11. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001;358: 1042-1045.
12. Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis treated with cyclosporine: a 5-yr cohort study. J Invest Dermatol 2003; 120: 211-6.
13. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998;39:464-75.
14. Griffiths CE, Katsambas A, Dijkmans BA, Finlay AY, Ho VC, Johnston A, et al. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol 2006;155:1-16.
15. Berth-Jones J, Henderson CA, Munro CS, Rogers S, Chalmers RJG, Boffa MJ, et al. Treatment of psoriasis with intermittent short course cyclosporine (Neoral). A multicenter study. Br J Dermatol 1997;136:527-30.
16. Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, León-Dorantes G, Atakan N, et al. Intermittent short courses of cyclosporine (Neoral) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 1999;141:283-91.
17. Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001;44:643-51.
18. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23:1-70.
19. Menter MA, See JA, Amend WJ, Ellis CN, Krueger GG, Lebwohl M, et al. Proceedings of the psoriasis combination and rotation therapy conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol 1996;34:315-21.
20. Griffiths CEM, Powles AV, McFadden J, Baker BS, Valdimarsson H, Fry L. Long term cyclosporine for psoriasis. Br J Dermatol 1989;120:256-66.
21. Ozawa A, Sugai J, Ohkido M, Ohtsuki M, Nakagawa H, Kitahara H, et al. Cyclosporin in psoriasis: continuous monotherapy versus intermittent longterm therapy. Eur J Dermatol 1999;9:218-23.
22. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebocontrolled study. J Am Acad Dermatol 1994;31:68-74.
23. Gottlieb SL, Heftler NS, Gilleaudeau P, Johnson R, Vallat VP, Wolfe J, et al. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study. J Am Acad Dermatol 1995;33:637-45.
24. Abel EA. Phototherapy: Uvb and PUVA. Cutis 1999;64:339-42.
25. Korstanje MJ, Hulsmans RF. Combination therapy cyclosporine A-PUVA in psoriasis. Acta Derm Venereol 1990;70:89-90.
26. Momtaz TK, Fitzpatrick TB. Modifications of PUVA. Dermatol Clin 1995;13:867-73.
27. van de Kerkhof PC. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol 2001;26:356-61.
28. van de Kerkhof PC, de Rooij MJ. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. Br J Dermatol 1997;136:275-8.
29. Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomized, double blind, placebo controlled, multicenter trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-64.
30. Mazzanti G, Coloni L, De Sabbata G, Paladini G. Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis: a pilot study. Acta Derm Venereol Suppl (Stockh) 1994;186:116-7.
31. Aydin F, Canturk T, Senturk N, Turanli AY. Methotrexate and cyclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol 2006;31:520-4.
32. Wong KC, Georgouras K. Low dose cyclosporin A and methotrexate in the treatment of psoriasis. Acta Derm Venereol 1999;79:87.
33. Gul U, Gonul M, Kilic A, Erdem R, Cakmak SK, Gunduz H. Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A. Clin Ther 2006;28:251-4.
34. Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, et al. Combination treatment with methotrexate and cyclosporine for severe recalcitrant psoriasis. Br J Dermatol 1999; 141:279-82.
35. Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49: 644-50.
36. Marquez C, Bair SM, Smithberger E, Cherpelis BS, Glass LF. Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. J Drugs Dermatol. 2010;9(7):753-8.
37. Lebwohl M. Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol 2003;49(Suppl):S118-24.
38. Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg 2005;24:37-45.
39. Stebbins WG, Lebwohl MG. Biologics in combination with nonbiologics: efficacy and safety. Dermatol Ther 2004;17:432-40.
40. Tuxen AJ, Yong MK, Street AC, Dolianitis C. Disseminated cryptococcal infection in a patient with severe psoriasis treated with efalizumab, methotrexate and cyclosporin. Br J Dermatol 2007;157:1067-8.
41. Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomized, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-64.
42. Mahrle G, Schulze HJ, Bräutigam M, Mischer P, Schopf R, Jung EG, et al. Anti-inflammatory efficacy of low-dose cyclosporine A in psoriatic arthritis. A prospective multicentre study. Br J Dermatol 1996;135:752-7.
43. Laburte C, Grossman R, Abi-Rached J et al. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130:366-375.
44. Paul CF, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 year cohort study. J Invest Dermatol. 2003; 120(2):211-16.
45. Shin Woo, Young Woon, et al. Cyclosporine treatment of Atopic Dermatitis: It is really associated with infectious diseases? Ann Dermatol 2010;22(2): 170-172.
46. Toyoda M, Morohashi M. Morphological assessment of the effects of cyclosporine A on Mast Cell- Nerve relationship in Atopic Dermatitis. Acta Derm Venereol (Stochkh) 1998;78: 321-325.
47. Th. Van J, Heule F et al. Cyclosporine in atopic dermatitis. Br J Dermatol. 1994; 130:634-640.
48. Haw S, Shin MK et al. The efficacy and Safety of Long-term Oral Cyclosporine treatment for patients with Atopic Dermatitis. Ann Dermatol. 2010;22(1):9-15.
49. Frankel HC, Frangos JE et al. Tapering cyclosporine after long term treatment for atopic dermatitis. J of Eur Acad Dermatol and Venereol. 2011. Jun 4.
50. Ohtsuka Tsutomu. Response to oral cyclosporine therapy and high sensitivity-CRP level in chronic idiopathic urticaria. Int J Dermatol 2010;49:579-584.
51. Kessel A. Toubi E. Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. Allergy 2010;65:1478-1482.
52. Hye YJ, Hei SK, et al. Cyclosporine treatment in a patient with concurrrent Autoimmune urticaria and Autoimmune Hepatitis. Ann Dermatol 2009;21(3):291-293.
53. Bertha-Jones J, Smith S G et al. Nodular prurigo responds to cyclosporine. Br J Dermatol 1995;132:795-799.
54. Wallengren J. Prurigo: diagnosis and management. Am J Clin Dermatol 2004;5 (2):85-95.
55. Lee. M, Shumack S. Prurigo Nodularis: A review. Australasian Journal of Dermatol 2005; 46:211-220.
56. Elgart G, Stover P, Larson K, Sutter C,et al. Treatment of pyoderma gangrenosum with cyclosporine: results in seven patients. J Am Acad Dermatol. 1991;24(1):83-6.
57. Hasselmann DO, Bens G, Tilgen W, Reichrath J. Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature. J Dtsch Dermatol Ges 2007;5:560-4
58. Reich A, Maj J, Cisło M, Szepietowski JC. Periungual lesions in pyoderma gangrenosum. Clin Exp Dermatol 2009;34(5):e81-4.
59. Reichrath J, Bens G, Bonowitz A, Tilgen W, Treatment recommendations for pyoderma gangrenosum: an evidence based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005;53:273-83.
60. Soria C, Allegue F, Martin M, Ledo A. Treatment of pyoderma gangrenosum with cyclosporine A. Clinical and experimental Dermatology.1991 Sep;16(5):392-394.
61. Turner RB, Emer JJ, Weill M, et al. Rapid resolution of pyoderma gangrenosum after treatment with intravenous cyclosporine. J Am Acad Dermatol. 2010;63(3):e72-4
62. Friedman S, Marion JF, Scherl E, Rubin PH, Present DH. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001;7:1-7
63. Azizan NZ, Gangaram HB, Hussein SH. A novel therapy for the treatment of pyoderma gangrenosum. Med J Malaysia 2008 Mar;63(1):51-4
64. Wenzel J, Gerdsen R, Phillipp-Dormston W, et al.Topical treatment of pyoderma gangrenosum. Dermatology 2002;205(3):221-3
65. Feliciani C, Tulli A. Topical cyclosporine in the treatment of dermatology diseases. Int J Immunopathol Pharmacol. 2002;15(2):89-93
66. Cohen PR. Neutrophilic Dermatoses : a review of the current treatment options. Am J Clin Dermatol 2009;10 (5):301-12.
67. Wilson DM, John GR, Callen JP. Peripheral ulcerative keratitis, an extracutaneous neutrophilic disorder: report of a patient with rheumathoid arthritis, pustular vasculitis, pyoderma gangrenosusm and Sweet's syndrome with an excellent response to cyclosporine treatment. J Am Acad Dermatol.1999;40:331- 4
68. Von Den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis) J Am Acad Dermatol 1994;314:535-56.
69. Von Den Driesch P. Sweet's syndrome-Therapy with cyclosporin. Clin Experimental Dermatol 1994; 19(3):274-7
70. Bourke JF, Bertha-Jones J, Graham-Brown RA. Sweet's syndrome responding to Cyclosporin. Br J Dermatol.1992; 127(1):36-8
71. Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003;4:449-65.
72. Panjwani S. Early diagnosis and treatment of discoid lupus erythematosus. J Am Board Fam Med. 2009;22:206-13.
73. Rothe MJ, Kerdel FA. Treatment of cutaneous lupus erythematosus. Lupus. 1992;1:351-6.
74. Ogawa H, Kameda H, Amano K, Takeuchi T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010;19:162-9.
75. Klein A, Vogt T, Wenzel SM, Fleck M, Landthaler M. Cyclosporin combined with methotrexate in two patients with recalcitrant subacute cutaneous lupus erythematosus. Australas J Dermatol. 2011;52:43-7.
76. Grabbe S, Kolde G. Coexisting lichen planus and subacute cutaneous lupus erythematosus. Clin Exp Dermatol. 1995;20:249-54.
77. Kontochristopoulos GJ, Giannadaki M, Doulaveri G, Christofidou E, Zakopoulou N. Psoriasis coexisting with subacute cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol. 2004;18:385-6.
78. Gruson LM, Cohen DE. Dermatomyositis. Dermatol Online J. 2004;10:7.
79. Rosa Neto NS, Goldenstein-Schainberg C. Juvenile dermatomyositis: review and update of the pathogenesis and treatment. Rev Bras Reumatol. 2010;50(3):299-312.
80. Arnson Y, Dovrish Z, Hadari R, Amital H. Amyopathic dermatomyositis - an uncommon presentation of dermatomyositis. Isr Med Assoc J. 2007;9:492-3.
81. Ytterberg SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep. 2006;8:167-73.
82. Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol. 2010;63:925-46.
83. Iorizzo LJ 3rd, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol. 2008;59:99-112.
84. Vencovský J, Jarosová K, Machácek S, Studýnková J, Kafková J, Bartůnková J, Nemcová D, Charvát F. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29:95-102.
85. Miyake S, Ohtani Y, Sawada M, Inase N, Miyazaki Y, Takano S, Miyasaka N, Yoshizawa Y. Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:128-33.
86. Mii S, Niiyama S, Kusunoki M, Arai S, Katsuoka K. Cyclosporine A as treatment of esophageal involvement in dermatomyositis. Rheumatol Int. 2006;27:183-5.
87. Shimojima Y, Ishii W, Kato T, Hoshi K, Matsuda M, Hashimoto T, Tanaka Y, Ikeda S. Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A. Intern Med. 2003;42:1253-8.
88. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part II. Treatment. J Am Acad Dermatol. 2010;62:191-202.
89. Ito T, Aoshima M, Ito N, Uchiyama I, Sakamoto K, Kawamura T, Yagi H, Hashizume H, Takigawa M. Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata. Arch Dermatol Res. 2009;301:373-80.
90. Shaheedi-Dadras M, Karami A, Mollaei F, Moravvej H, Malekzad F. The effect of methylprednisolone pulse-therapy plus oral cyclosporine in the treatment of alopecia totalis and universalis. Arch Iran Med. 2008;11:90-3. Erratum in: Arch Iran Med. 2008 Mar;11(2):241.
91. Kim BJ, Min SU, Park KY, Choi JW, Park SW, Youn SW, Park KC, Huh CH. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. J Dermatolog Treat. 2008;19:216-20.
92. Alpsoy E, Akman A. Behçet's disease: an algorithmic approach to its treatment. Arch Dermatol Res. 2009;301:693-702.
93. Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gonçalves O, Valente J.Behçet's disease - a contemporary review. J Autoimmun. 200;32:178-88.
94. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kötter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stübiger N, Yurdakul S, Yazici H; EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-62.
95. Lin P, Liang G. Behçet disease: recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol. 2006 ;12:282-6.
96. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005;50:297-350.
97. Spadino S, Altomare A, Cainelli C, Franchi C, Frigerio E, Garutti C, Taglioni M, Altomare GF. Disseminated granuloma annulare: efficacy of cyclosporine therapy. Int J Immunopathol Pharmacol. 2006;19:433-8.
98. Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol. 2008;47:29-35.
99. Antic M, Lautenschlager S, Itin PH. Eosinophilic fasciitis 30 years after -what do we really know? Report of 11 patients and review of the literature. Dermatology. 2006;213(2):93-101.
100. Valencia IC, Chang A, Kirsner RS, Kerdel FA. Eosinophilic fasciitis responsive to treatment with pulsed steroids and cyclosporine. Int J Dermatol. 1999 May;38:369-72.
101. Bukiej A, Dropiński J, Dyduch G, Szczeklik A. Eosinophilic fasciitis successfully treated with cyclosporine. Clin Rheumatol. 2005;24:634-6.
102. Tǎmaş MM, Baican C, Rednic S. Hyperimmunoglobulin E syndrome (Job's syndrome). Rom J Intern Med. 2008;46:169-71.
103. DeWitt CA, Bishop AB, Buescher LS, Stone SP. Hyperimmunoglobulin E syndrome: two cases and a review of the literature. J Am Acad Dermatol. 2006;54:855-65.
104. Wolach B, Eliakim A, Pomeranz A, Cohen AH, Nusbacher J, Metzker A. Cyclosporin treatment of hyperimmunoglobulin E syndrome. Lancet 1996;347:67.
105. Schepis C, Lentini M, Siragusa M. Erosive lichen planus on an atypical site mimicking a factitial dermatitis. Acta Derm Venereol. 2010;90:185-6.
106. Schepis C, Siragusa M, Lentini M. Erosive lichen planus: two uncommon cases. Acta Derm Venereol. 2008;88:268-70.
107. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci. 2007 Jun;49(2):89-106. Review. PubMed PMID: 17634721.
108. Mirmirani P, Willey A, Price VH. Short course of oral cyclosporine in lichen planopilaris. J Am Acad Dermatol. 2003;49:667-71.
109. Lane TK, Kamino H, Walters RF, Meehan S, Pomeranz MK. Lichen planopilaris and psoriasis. Dermatol Online J. 2008;14:4.
110. Bulbul Baskan E, Turan H, Tunali S, Toker SC, Saricaoglu H. Open-label trial of cyclosporine for vulvar lichen sclerosus. J Am Acad Dermatol. 2007;57:276-8.
111. Schiavo AL, Puca RV, Ruocco V, Ruocco E. Adjuvant drugs in autoimmune bullous iseases, efficacy versus safety: Facts and controversies. Clin Dermatol. 2010;28:337-43.
112. Olszewska M, Kolacinska-Strasz Z, Sulej J, Labecka H, Cwikla J, Natorska U, Blaszczyk M. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 2007;8:85-92.
113. Tirado-Sánchez A, León-Dorantes G. Treatment of pemphigus vulgaris. An overview in Mexico. Allergol Immunopathol (Madr). 2006 Jan;34:10-6.
114. Chrysomallis F, Ioannides D, Teknetzis A, Panagiotidou D, Minas A. Treatment of oral pemphigus vulgaris. Int J Dermatol. 1994;33:803-7.
115. Alsaleh QA, Nanda A, Al-Baghli NM, Dvorak R. Pemphigus in Kuwait. Int J Dermatol. 1999;38:351-6.
116. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006263.
117. Millard TP, Hawk JL. Photosensitivity disorders: cause, effect and management. Am J Clin Dermatol. 2002;3:239-46.
118. Stinco G, Codutti R, Frattasio A, De Francesco V, Patrone P. Chronic actinic dermatitis treated with cyclosporine-A. Eur J Dermatol. 2002;12:455-7.
119. Booth AV, Ma L. Pityriasis rubra pilaris, type 1. Dermatol Online J. 2005;11:9.
120. Usuki K, Sekiyama M, Shimada T, Shimada S, Kanzaki T. Three cases of pityriasis rubra pilaris successfully treated with cyclosporin A. Dermatology. 2000;200:324-7.
121. Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy. 2010;2:863-78.
122. Ippoliti G, Miori L, Negri M, Rovati B, Lorenzutti F, Zerbinati N, Rabbiosi G. Cyclosporine in treatment of progressive systemic sclerosis: clinical and immunologic findings. Transplant Proc. 1994;26:3117-8.
123. Morton SJ, Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxford). 2000;39:865-9.
124. Worswick S, Cotliar J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options. Dermatol Ther. 2011;24:207-18.
125. Kumari R, Timshina DK, Thappa DM. Drug hypersensitivity syndrome. Indian J Dermatol Venereol Leprol. 2011;77:7-15.
126. Rajaratnam R, Mann C, Balasubramaniam P, Marsden JR, Taibjee SM, Shah F, Lim R, Papini R, Moiemen N, Lewis H. Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre. Clin Exp Dermatol.2010;35:853-62.
127. Paquet P, Piérard GE. New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited. Drug Saf. 2010;33:189-212.
128. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2006;97:272-80.
129. Matsushita K, Ozaki A, Inoue H, Kaieda T, Akimoto M, Satomura A, Arima N, Hamada H, Suruga Y, Aoki N, Fujiwara H, Tei C. Stevens-Johnson syndrome induced by mizoribine in a patient with systemic lupus erythematosus. Mod Rheumatol. 2006;16:113-6.
130. Peru H, Soylemezoglu O, Bakkaloglu SA, Elmas S, Bozkaya D, Elmaci AM, Kara F, Buyan N, Hasanoglu E. Henoch Schonlein purpura in childhood: clinical analysis of 254 cases over a 3-year period. Clin Rheumatol. 2008;27:1087-92.
131. Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol. 2006;24:414-29.
132. Venzor J, Lee WL, Huston DP. Urticarial vasculitis. Clin Rev Allergy Immunol. 2002;23:201-16.
133. Tsutsui K, Hirone T, Kubo K, Matsui Y. Annular elastolytic giant cell granuloma: response to cyclosporin A. J Dermatol. 1994;21:426-9.
134. Hayashi M, Kawaguchi M, Mitsuhashi Y, Suzuki T. Case of hypereosinophilic syndrome with cutaneous necrotizing vasculitis. J Dermatol. 2008;35:229-33.
135. Shenoy VV, Joshi SR, Kotwal VS, Shedge RT, Ramraje NN, Lanjewar DN. Recurrent Kimura's disease: excellent response to cyclosporine. J Assoc Physicians India. 2006;54:153-5.
136. Birol A, Bozdogan O, Keleş H, Kazkayasi M, Bagci Y, Kara S, Koçak M, Birol A. Kimura's disease in a Caucasian male treated with cyclosporine. Int J Dermatol. 2005;44:1059-60.
137. Sugita K, Kabashima K, Koga C, Tokura Y. Eosinophilic pustular folliculitis successfully treated with sequential therapy of interferon-gamma and ciclosporin. Clin Exp Dermatol. 2006 Sep;31:709-10.
138. Palamaras I, El-Jabbour J, Pietropaolo N, Thomson P, Mann S, Robles W, Stevens HP. Metastatic Crohn's disease: a review. J Eur Acad Dermatol Venereol. 2008;22:1033-43.
139. Carranza DC, Young L. Successful treatment of metastatic Crohn's disease with cyclosporine. J Drugs Dermatol. 2008;7:789-91.
140. Stanway A, Rademaker M, Newman P. Healing of severe ulcerative necrobiosis lipoidica with cyclosporin. Australas J Dermatol. 2004;45:119-22.
141. Migliore A, Bizzi E, Santacroce CM, Tarquini E, Massafra U, Vacca F, Martin Martin LS. Mixed panniculitis responding to cyclosporin-A with a 12-month follow-up: a case report. Int J Immunopathol Pharmacol. 2009;22:1143-6.
142. Rojnuckarin P, Nakorn TN, Assanasen T, Wannakrairot P, Intragumtornchai T. Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma. 2007;48:560-3.
143. Al Zolibani AA, Al Robaee AA, Qureshi MG, Al Nosian H. Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome successfully treated with cyclosporin A. Skinmed. 2006;5:195-7.
144. Tajima M, Mitsuhashi Y, Irisawa R, Amagai M, Hashimoto T, Tsuboi R. IgA pemphigus reacting exclusively to desmoglein 3. Eur J Dermatol. 2010;20:626-9. Erratum in: Eur J Dermatol. 2011;21:152.
145. Gergely L, Váróczy L, Vadász G, Remenyik E, Illés A. Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A. Acta Haematol. 2003;109:202-5.
146. Valdés E, Núñez T, Pedraza D, Muñoz H. Recurrent Impetigo Herpetiformis: successfully managed with ciclosporine. Report of one case. Rev Med Chil. 2005;133:1070-4.
147. Bata-Csorgo Z, Husz S, Foldes M, Korom I, Molnar K, Morvay M, Dobozy A. Scleromyxedema. J Am Acad Dermatol. 1999;41(2 Pt 2):343-6.
148. Saigoh S, Tashiro A, Fujita S, Matsui M, Shibata S, Takeshita H, Duan H, Moroi Y, Urabe K, Koga T, Furue M. Successful treatment of intractable scleromyxedema with cyclosporin A. Dermatology. 2003;207:410-1.
149. Nakajima K, Ikeda M, Nakajima H, Kodama H. Regression of secondary plane xanthomas using cyclosporine A. Int J Dermatol. 2006;45:1136-8.